Entera Bio

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. The company currently conducts clinical trials utilizing its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract. Entera Bio's technology addresses the two major problems of oral drug delivery of large-molecule active pharmaceutical ingredients. Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. Entera's proprietary technologies act synergistically to transport and protect large molecules. The company is developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Entera Bio is subsidiary of DNA Biomedical Solutions.

Entera Bio has raised $58.9M in total funding across 7 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), D.N.A Biomedical Solutions Ltd, Pontifax.

Entera Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology, Healthcare, Patients.

Entera Bio is based in Jerusalem, Israel, Jerusalem District.